<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE GlossaryTerm >
<GlossaryTerm id="CDR0000749332"><TermName>Sylatron</TermName><TermPronunciation>(SY-luh-tron)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat melanoma in patients who have had surgery to remove cancer that has spread to lymph nodes.  It is also being studied in the treatment of other types of cancer.  Sylatron is a brand name for peginterferon alfa-2b. It is a type of cytokine and a type of biological response modifier.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000752611" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Sylatron&quot;" language="en" id="_3"/><MediaLink ref="CDR0000752610" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Sylatron&quot;" language="es" id="_4"/><SpanishTermName>Sylatron</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para tratar el melanoma en pacientes que se han operado a fin de extirpar el cáncer que se diseminó hacia los ganglios linfáticos.   También está en estudio para tratar otros tipos de cáncer. Sylatron es el nombre comercial del peginterferón α-2b.   Es un tipo de citocina y un tipo de modificador de la respuesta biológica.  </DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2013-05-09</DateFirstPublished><RelatedInformation><RelatedDrugSummaryRef href="CDR0000746606">Peginterferon Alfa-2b</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
